Nephropathy News and Research

RSS

Nephropathy is a broad medical term used to denote disease or damage of the kidney, which can eventually result in kidney failure. The primary and most obvious functions of the kidney are to excrete any waste products and to regulate the water and acid-base balance of the body – therefore loss of kidney function is a potentially fatal condition.

Thomson Reuters's NeoFax deployed at the University of Kansas Hospital for electronic neonatal drug dosing

The University of Kansas Hospital has deployed NeoFax(®) from Thomson Reuters to provide physicians, nurses, and pharmacy staff in its neonatal intensive care unit with electronic drug dosing, interaction checking, and reference information.

13 Oct 2009

Kidney Care Partners commends CBC for supporting reforms to improve access to quality kidney care

Kidney Care Partners - an alliance of patient advocates, dialysis professionals, care providers and manufacturers working together to improve quality of care for individuals with kidney disease and kidney failure - today applauded the Congressional Black Caucus (CBC) for supporting reforms that will improve patient access and choice in receiving quality kidney care.

13 Oct 2009

VitalProteinRx nutritional supplement for chronic kidney disease affected patients

VitalRemedyMD, a physician-established company, offers scientifically formulated integrative nutritional supplements designed to improve the quality of traditional healthcare. "We are proud that VitalProteinRx is now an integral part of Fresenius' armamentarium in helping patients with chronic kidney disease," stated Dr. Seth Baum, Founder of VitalRemedyMD.

13 Oct 2009

Wake Forest University School of Medicine honours researchers

Wake Forest University School of Medicine honored eight of its researchers with awards for excellence at the 13th Annual Research Awards Day Oct. 1.

12 Oct 2009

NOXXON Pharma announces the successful completion of the first phase I trial of Spiegelmer NOX-E36

NOXXON Pharma AG, the biopharmaceutical company focusing on the development of novel drugs based on its unique proprietary Spiegelmer® technology, today announced successful completion of the first phase I trial with its anti-inflammatory Spiegelmer® NOX-E36. This drug candidate will be developed for the treatment of complications of type 2 diabetes, preferentially diabetic nephropathy, but also others.

12 Oct 2009

MEDLINE multi-purpose electronic database helps doctors care for their patients

Research funded by The Kidney Foundation of Canada and led by kidney specialists at Lawson Health Research Institute and The University of Western Ontario will make it possible for doctors to quickly and effectively access information relevant for patient care.

12 Oct 2009

WCMC-Q program highlights the importance of mental health to overall physical health

Mental health professionals from Weill Cornell Medical College in Qatar and the community highlighted the importance of mental health to overall physical health during a presentation Sunday as part of the medical college's recognition of World Mental Health Day.

12 Oct 2009

Exercise offers significant health benefits for patients with chronic kidney dysfunction

Getting off the couch could lead to a longer life for kidney disease patients, according to a study appearing in an upcoming issue of the JClinical Journal of the American Society Nephrology (CJASN).

9 Oct 2009

AMAG Pharmaceuticals to present three abstracts at ASN Renal Week meeting

AMAG Pharmaceuticals, Inc. today announced that three abstracts have been accepted for presentation at the American Society of Nephrology (ASN) Renal Week meeting being held October 27-November 1, 2009 in San Diego, CA.

8 Oct 2009

Relypsa commences patient enrollment in Phase 2b clinical trial of RLY5016 for treating hyperkalemia

Relypsa, Inc., today announced the initiation of patient enrollment in the PEARL-HF study, a Phase 2b clinical trial of the company’s lead compound, RLY5016. A novel potassium binder designed for chronic use, RLY5016 is being evaluated in the prevention and treatment of hyperkalemia, for which there are no current satisfactory treatments.

7 Oct 2009

Shire publishes efficacy study results of FOSRENOL and Renagel

Shire plc, the global specialty biopharmaceutical company, today announces the publication in Clinical Nephrology of findings from a head-to-head clinical study comparing the efficacy of two non-calcium based phosphate binders, FOSRENOL(R) (lanthanum carbonate) and sevelamer hydrochloride (Genzyme's Renagel(R)) in chronic kidney disease (CKD) patients on haemodialysis.

7 Oct 2009

Diuretics effective as second-line agents in treating high blood pressure

A new review shows that diuretics — drugs often recommended as a first-line treatment for high blood pressure — are also effective when added as a second agent to other blood-pressure lowering drugs.

7 Oct 2009

Fresenius Medical Care to offer seasonal influenza and H1N1 flu vaccines

As the Centers for Disease Control and Prevention (CDC) predicts a more severe flu season this year, people with chronic health conditions are especially at risk and can develop a more severe illness from any influenza infection, including the H1N1 virus.

6 Oct 2009

Gilbert Hospital to provide renal dialysis services

There is a growing need for renal care, specifically, dialysis and proportionally, that growth is right here in the Valley" said David Wanger, the hospital's chief executive officer.

6 Oct 2009

Data for end-stage kidney disease in the United States available online

Incidence and prevalence data for end-stage kidney disease in the United States will be available online from the U.S. Renal Data System a year earlier than usual, announces the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), part of the National Institutes of Health. In addition, the data will be updated online every three months and will show quarterly counts of patients at www.usrds.org/qtr/qrt_report_table_new.html.

3 Oct 2009

Study finds link between allergic inflammation and nephropathy in men with type 2 diabetes

For men with type 2 diabetes, a cell type linked to allergic inflammation is closely linked to a key indicator of diabetic kidney disease (nephropathy), suggests a study in the November Clinical Journal of the American Society of Nephrology (CJASN). "Allergy is a common disease that is increasing worldwide, so our findings may have important implications for diabetic nephropathy," comments Michiaki Fukui, MD (Kyoto Prefectural University of Medicine, Japan).

3 Oct 2009

American Kidney Fund to host national gala to support kidney care community

In celebration of people who are living with kidney disease, as well as the individuals and corporations who are working to improve the lives of kidney patients, the American Kidney Fund will host its first national gala, The Hope Affair, at the Newseum on October 6.

3 Oct 2009

Study reveals how kidney repair processes are controlled

A study by Monash University researchers has shed new light on the microscopic antennas in the kidney that are involved in the organ's repair process.

1 Oct 2009

Medgenics announces unaudited half-yearly results for the six months ended 30 June 2009

Medgenics (AIM:MEDG) (AIM:MEDU) is pleased to announce its unaudited half-yearly results for the six months ended 30 June 2009.

30 Sep 2009

Dynavax commences Phase 3 trial for HEPLISAV hepatitis B vaccine

Dynavax Technologies Corporation (Nasdaq:DVAX) today announced the initiation of a Phase 3 registration trial for HEPLISAVTM hepatitis B vaccine in individuals with chronic kidney disease. A second registration trial, a Phase 3 lot-to-lot consistency trial, is expected to begin in early 2010. HEPLISAV is an investigational adult hepatitis B vaccine designed to provide increased, rapid protection with fewer doses than current licensed vaccines.

29 Sep 2009

Nephropathy News and Research

Further Reading

Thomson Reuters's NeoFax deployed at the University of Kansas Hospital for electronic neonatal drug dosing

Kidney Care Partners commends CBC for supporting reforms to improve access to quality kidney care

VitalProteinRx nutritional supplement for chronic kidney disease affected patients

Wake Forest University School of Medicine honours researchers

NOXXON Pharma announces the successful completion of the first phase I trial of Spiegelmer NOX-E36

MEDLINE multi-purpose electronic database helps doctors care for their patients

WCMC-Q program highlights the importance of mental health to overall physical health

Exercise offers significant health benefits for patients with chronic kidney dysfunction

AMAG Pharmaceuticals to present three abstracts at ASN Renal Week meeting

Relypsa commences patient enrollment in Phase 2b clinical trial of RLY5016 for treating hyperkalemia

Shire publishes efficacy study results of FOSRENOL and Renagel

Diuretics effective as second-line agents in treating high blood pressure

Fresenius Medical Care to offer seasonal influenza and H1N1 flu vaccines

Gilbert Hospital to provide renal dialysis services

Data for end-stage kidney disease in the United States available online

Study finds link between allergic inflammation and nephropathy in men with type 2 diabetes

American Kidney Fund to host national gala to support kidney care community

Study reveals how kidney repair processes are controlled

Medgenics announces unaudited half-yearly results for the six months ended 30 June 2009

Dynavax commences Phase 3 trial for HEPLISAV hepatitis B vaccine

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News